ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
100.78
-0.47 (-0.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close101.25
Open101.49
Bid96.00 x 800
Ask101.88 x 800
Day's Range100.57 - 101.81
52 Week Range34.53 - 114.20
Volume416,989
Avg. Volume480,058
Market Cap3.879B
Beta (3Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)-6.10
Earnings DateFeb 19, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est107.37
Trade prices are not sourced from all markets
  • IQ merger arbitrage ETF bets on strong M&A space
    Yahoo Finance Video

    IQ merger arbitrage ETF bets on strong M&A space

    The merger and acquisitions space is looking strong, topping $40 billion in deals for the first Monday in June, according to recent data. Sal Bruno, Chief Investment Officer at IndexIQ, joins Seana Smith on 'The Ticker' to discuss how this ETF can diversify investor portfolios.

  • Tender offer deadline in $4.3B Roche-Spark deal pushed back for a fifth time.
    American City Business Journals

    Tender offer deadline in $4.3B Roche-Spark deal pushed back for a fifth time.

    The proposed sale of the Philadelphia gene therapy pioneer continues to be delayed by ongoing regulatory reviews by the FTC and CMA.

  • Benzinga

    The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals ...

  • Analysts Estimate Spark Therapeutics (ONCE) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Spark Therapeutics (ONCE) to Report a Decline in Earnings: What to Look Out for

    Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised
    Zacks

    Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised

    Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

  • The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On
    Motley Fool

    The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On

    Gene therapy developers might steal all of the headlines, but manufacturing is likely to be the more lucrative investing opportunity -- for both companies and investors.

  • Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
    Zacks

    Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)

    Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.

  • Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline
    Zacks

    Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline

    Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.

  • BioMarin (BMRN) to File for Hemophilia A Candidate in Q4
    Zacks

    BioMarin (BMRN) to File for Hemophilia A Candidate in Q4

    BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.

  • Spark, Roche extend deadline for completing $4.3 billion merger into early 2020
    American City Business Journals

    Spark, Roche extend deadline for completing $4.3 billion merger into early 2020

    The deadline was extended to provide more time to deal with antitrust regulators in the United States and the United Kingdom, who must approve the proposed Roche-Spark merger.

  • Reuters

    Roche, Spark push back takeover deadline in $4.3 billion deal

    Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker's $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year. The new deadline for both companies to extend the merger agreement is now April 30, 2020, rather than Jan. 31, 2020, Roche said in a U.S. regulatory filing on Monday, saying the change provides "additional time to clear the transaction". Roche's March 5 bid to add Spark's gene therapy technology is dragging on, with completion pushed back several times as the Swiss company blames time-consuming U.S. Federal Trade Commission scrutiny of any competition issues.

  • Reuters

    UPDATE 1-Roche, Spark push back takeover deadline in $4.3 bln deal

    Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker's $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year. The new deadline for both companies to extend the merger agreement is now April 30, 2020, rather than Jan. 31, 2020, Roche said in a U.S. regulatory filing on Monday, saying the change provides "additional time to clear the transaction". Roche's March 5 bid to add Spark's gene therapy technology is dragging on, with completion pushed back several times as the Swiss company blames time-consuming U.S. Federal Trade Commission scrutiny of any competition issues.

  • Despite Recent Volatility, Biotech Stocks Look Poised to Pop
    Investopedia

    Despite Recent Volatility, Biotech Stocks Look Poised to Pop

    Recent news from a leading gene therapy company highlights the risks, but the charts suggest ample room to the upside for biotech stocks.

  • Markit

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ONCE with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ONCE are favorable, with net inflows of $2.63 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst
    Investor's Business Daily

    Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst

    Gene therapy player Uniqure could head to the auction block, an analyst said Monday as shares of the biotech company popped. He also said Roche's plan to buy Spark Therapeutics could falter.

  • Roche's $4.8 Billion Buyout Of Spark Delayed Amid Competitive Worries
    Investor's Business Daily

    Roche's $4.8 Billion Buyout Of Spark Delayed Amid Competitive Worries

    Spark Therapeutics stock tumbled Monday after Swiss biopharma Roche delayed its $4.8 billion takeover of the biotech as regulators in the U.S. and Europe scrutinized the transaction.

  • Benzinga

    Roche Extends Deadline For Spark Acquisition As US, UK Regulators Seek Additional Information

    The expiration date of Roche's offer has been extended from 5 p.m. Friday, June 14 to 5 p.m. July 31, which suggests Spark shareholders now have until July 31 to tender their shares. Roche has a lot riding on the Spark deal given the pharma giant's recent focus on gene therapies. Spark already has an approved gene therapy, Luxturna, for inherited retinal disease, and more investigational therapies in the pipeline for hemophilia A, hemophilia B, lysosomal storage disorders and neurodegenerative diseases.

  • TheStreet.com

    Spark Therapeutics' Shares Fall on Roche Acquisition Delay

    may be delayed beyond the second quarter amid additional scrutiny from U.S. regulators. The companies said on Monday they had each received requests for additional information and documentary material from the U.S. Federal Trade Commission in connection with its review of the pending acquisition, prompting Roche to extend the tender offer period until next month. Because it is a "second request" from the FTC, part of the regulatory review process, the offer's waiting period has been extended from June 14 to July 31, the companies said in a statement on Monday.

  • $4.8 billion deal for gene therapy pioneer Spark Therapeutics delayed once more
    American City Business Journals

    $4.8 billion deal for gene therapy pioneer Spark Therapeutics delayed once more

    With more questions coming from the FTC, Roche has extended the deadline of its tender offer for a fourth time.

  • Roche Receives FTC Request for Further Data on Spark Buyout
    Zacks

    Roche Receives FTC Request for Further Data on Spark Buyout

    Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.

  • Reuters

    UPDATE 1-Roche's $4.3 bln Spark bid delayed again amid U.S., UK scrutiny

    Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition. Roche said on Monday that both companies received a request for more information from the U.S. Federal Trade Commission in connection with the FTC's review of the deal, sending Spark shares down nearly 15% at $93 in premarket trading on Monday. Roche also said that the UK Competition and Markets Authority (CMA) has opened an investigation.